Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1877)

ACCEPTANCE OF REGISTRATION OF THE MEDIUM TERM NOTES BY THE NATIONAL ASSOCIATION OF FINANCIAL MARKET INSTITUTIONAL INVESTORS

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 28 December 2025.

The Company has recently received the Notice of Acceptance for Registration (Zhong Shi Xie Zhu (中市協注) [2025] No. MTN1249) (the "**Notice**") issued by the National Association of Financial Market Institutional Investors (the "**NAFMII**"). The NAFMII accepted the registration of the technology innovation bonds of the Company with the following specifications:

(1) The basic type registered by the Company is medium term notes, with the registered amount of the medium term notes of the Company being RMB20 billion. Such registered amount will be valid for 2 years commencing from the date of this Notice, and will be underwritten by Bank of Shanghai Co., Ltd.* (上海銀行股份有限公司).

(2) The Company may issue the technology innovation bonds in tranches during the validity period, subject to any prior filing requirement with the NAFMII if proceeding. The management of the issuance of such bonds of the Company must be conducted in accordance with the resolutions of the competent authorities and relevant management requirements. Upon completion, the issuance results shall be disclosed through channels recognised by NAFMII.

In accordance with the requirements of relevant laws and regulations and the authorization granted by the general meeting of the Company, the Company will issue technology innovation bonds according to capital needs and market conditions within the prescribed validity period, and make the disclosure in a timely manner in accordance with relevant requirements.

As the issuance of the medium term notes may or may not proceed, shareholders of the Company and potential investors are advised to exercise cautiously when dealing in the securities of the Company.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 28 December 2025

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as independent non-executive Directors.

* *For identification purposes only*